Adjust to target in type 2 diabetes - Comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine

被引:120
作者
Bergenstal, Richard M. [1 ]
Johnson, Mary [1 ]
Powers, Margaret A. [1 ]
Wynne, Alan [2 ]
Vlajnic, Aleksandra [3 ]
Hollander, Priscilla [4 ]
Rendell, Marc [5 ]
机构
[1] Int Diabet Ctr Pk Nicollet, Minneapolis, MN 55416 USA
[2] Cotton ONeil Clin, Topeka, KS USA
[3] Sanofi Aventis US, Bridgewater, NJ USA
[4] Baylor Endocrine Ctr, Dallas, TX USA
[5] Creighton Diabet Ctr, Omaha, NE USA
关键词
D O I
10.2337/dc07-2137
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE - Carbohydrate counting is an effective approach to mealtime insulin adjustment in type I diabetes but has not been rigorously assessed in type 2 diabetes. We sought to compare an insulin-to-carbohydrate ratio with a simple algorithm for adjusting the dose of prandial insulin glusiline. RESEARCH AND DESIGN METHODS - This 24-week, multicenter, randomized, controlled study compared two algorithms for adjusting mealtime (glulisine) insulin along with a standard algorithm for adjusting background (glargine) insulin in 273 intent-to-treat patients with type 2 diabetes. Glulisine and glargine were adjusted weekly in both groups based on self-monitored blood glucose (SMBG) results from the previous week. The simple algorithm group was provided set doses of glulisine to take before each meal. The carbohydrate counting (carb count) group was provided an insulin-to-carbohydrate ratio to use for each meal and adjusted their glulisine dose based on the amount of carbohydrate consumed. RESULTS - A1C levels at week 24 were 6.70% (simple algorithm) and 6.54% (carb count). The respective mean A1C changes from baseline to 24 weeks were - 1.46 and - 1.59% (P = 0.24). A1C <7.0% was achieved by 73.2% (simple algorithm) and 69.2% (carb count) (P = 0.70) of subjects; respective values for A1C <6.5% were 44.3 and 49.5% (P = 0.28). The total daily dose of insulin was lower, and there was a trend toward less weight gain in carb count group patients. Severe hypoglycemia rates were low and equal in the two groups. CONCLUSIONS - Weekly basal-bolus insulin adjustments based on premeal and bedtime glucose patterns resulted in significant reductions in A1C. Having two effective approaches to delivering and adjusting rapid-acting mealtime insulin may increase physicians' and patients willingness to advance therapy to a basal-bolus insulin regimen.
引用
收藏
页码:1305 / 1310
页数:6
相关论文
共 25 条
  • [1] *AM COLL END AM AS, 2002, ENDOCR PRACT, V8, P41
  • [2] Am Diabetes Assoc, 2006, DIABETES CARE, V29, pS4
  • [3] Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial
    Amiel, S
    Beveridge, S
    Bradley, C
    Gianfrancesco, C
    Heller, S
    James, P
    McKeown, N
    Newton, D
    Newton, L
    Oliver, L
    Reid, H
    Roberts, S
    Robson, S
    Rollingson, J
    Scott, V
    Speight, J
    Taylor, C
    Thompson, G
    Turner, E
    Wright, F
    [J]. BRITISH MEDICAL JOURNAL, 2002, 325 (7367): : 746 - 749
  • [4] Should postprandial glucose be routinely measured and treated to a particular target? No!
    Buse, JB
    [J]. DIABETES CARE, 2003, 26 (05) : 1615 - 1618
  • [5] Postprandial hyperglycemia and diabetes complications - Is it time to treat?
    Ceriello, A
    [J]. DIABETES, 2005, 54 (01) : 1 - 7
  • [6] Insulin glulisine provides improved glycemic control in patients with type 2 diabetes
    Dailey, G
    Rosenstock, J
    Moses, RG
    Ways, K
    [J]. DIABETES CARE, 2004, 27 (10) : 2363 - 2368
  • [7] Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin
    De Leeuw, I
    Vague, P
    Selam, JL
    Skeie, S
    Lang, H
    Draeger, E
    Elte, JWF
    [J]. DIABETES OBESITY & METABOLISM, 2005, 7 (01) : 73 - 82
  • [8] Efficacy and safety of insulin glulisine in patients with type 1 diabetes
    Dreyer, M
    Prager, R
    Robinson, A
    Busch, K
    Ellis, G
    Souhami, E
    Van Leendert, R
    [J]. HORMONE AND METABOLIC RESEARCH, 2005, 37 (11) : 702 - 707
  • [9] Garg Satish K, 2005, Endocr Pract, V11, P11
  • [10] Novel insulins: Expanding options in diabetes management
    Gerich, JE
    [J]. AMERICAN JOURNAL OF MEDICINE, 2002, 113 (04) : 308 - 316